Prophylactic Intramyometrial Oxytocin before Placenta Delivery during Cesarean Section Prevents Postpartum Hemorrhage: A Prospective Randomized Study of 150 Women

Divya Mangla, JK Goel, Ruchica Goel

ABSTRACT

Objectives: To compare efficacy of intramyometrial oxytocin vs intravenous oxytocin infusion in reducing blood loss during cesarean section.

Materials and methods: A prospective randomized controlled trial of 150 women undergoing cesarean section was done. Women undergoing cesarean section were randomly divided into three groups according to method of administration of oxytocin. In group I (n = 50): 20 units of oxytocin in 500 cc of ringer lactate as continuous infusion I/V after separation of placenta was given. In group II (n = 50): 5 units of oxytocin is diluted in 10 cc of normal saline and 5 cc injected in each cornu of uterus after separation of placenta. In group III (n = 50): 5 units of oxytocin is diluted in 10 cc of normal saline and 5 cc injected in each cornu of uterus before separation of placenta. Blood loss was calculated by number of mops soaked and amount of blood in suction jar.

Results: Average blood loss was found to be more in group I 606 cc, while in group II average blood loss was 460 ml which further decreased to 412 cc in group III. There was an additional observation that the 6% cases where I/V oxytocin infusion could not prevent uterine atony while immediate uterine contraction was achieved with intramyometrial oxytocin.

Conclusion: Intramyometrial injection of oxytocin when given before separation of placenta was found to be the most effective method to increase uterine contraction, reducing incidence of postpartum hemorrhage and thus decreasing cesarean morbidity.

Keywords: Intramyometrial oxytocin, Cesarean, Postpartum hemorrhage.

How to cite this article: Mangla D, Goel JK, Goel R. Prophylactic Intramyometrial Oxytocin before Placenta Delivery during Cesarean Section Prevents Postpartum Hemorrhage: A Prospective Randomized Study of 150 Women. J South Asian Feder Obst Gynae 2012;4(2):93-96.

Source of support: Nil

Conflict of interest: None

INTRODUCTION

Globally about 11% of women having live birth have severe postpartum hemorrhage (PPH) amounting to 14 million women a year. Major burden of this is born by women in underdeveloped and developing countries. The incidence of PPH is 3 to 6% of all normal deliveries. The incidence is higher in developed and developing countries. The incidence of PPH is 14 million women a year. Major burden of this is born by women in underdeveloped and developing countries. The incidence of PPH is 3 to 6% of all normal deliveries. The incidence is higher in developed and developing countries. The incidence of PPH is 14 million women a year. Major burden of this is born by women in underdeveloped and developing countries. The incidence of PPH is 3 to 6% of all normal deliveries. The incidence is higher in developed and developing countries.
jar and the number of sponges soaked with blood, amount of bleeding per vaginum was also noted during 1st hour after operation.

3. Need for extra dose of antiemetic was recorded in each group.

4. Baseline systolic blood pressure was obtained prior to uterine incision by attending anesthetist. Systolic blood pressure was recorded after injection of study solutions for 15 minutes at intervals of 5 minutes each.

Postoperatively patient was reassessed for her general condition, hemoglobin, etc. Baby outcome was also recorded.

**OBSERVATIONS**

In our study though in most of the women I/V infusion and intramyometrial injection of oxytocin resulted in similar effective uterine contractions yet in three women of group I where I/V infusion failed to contract uterus, an intramyometrial injection given in these women got uterus contracted immediately.

The blood loss in various groups was compared, as shown in Table 2. In group I, maximum number of women, i.e. 60% had blood loss ranging from 501 to 700 cc followed by 20% in the range of 301 to 500 cc. Fourteen percent women had blood loss in the range of 701 to 900 cc and in 6% blood loss was more than 900 cc. In group II, 70% of the women had blood loss in the range of 301 to 500 cc followed by 18% in range of 501 to 700 cc, none had blood loss >900 cc. In group III, 72% of the women had blood loss in the range of 301 to 500 cc while 14% women had blood loss in the range of 501 to 700 cc; only one patient had blood loss more than 700 cc.

Average blood loss in group I was 606 ml, group II was 460 ml and group III was 412 ml as shown in Graph 1.

Comparison of peroperative requirement of additional antiemetics was also done among three groups and it was observed that in group I, 20% of the women required additional antiemetics because of peroperative nausea and vomiting while in groups II and III, only 2% of women required additional antiemetics.

Changes in systolic blood pressure were noted and compared in various groups, as shown in Table 3. Systolic blood pressure was found to decrease in all groups but maximum decrease was found in group I. Sixty-two percent women in group I showed the decrease in systolic blood pressure in the range of

<table>
<thead>
<tr>
<th>Blood loss (ml)</th>
<th>Group 1 (IV infusion)</th>
<th>Group 2 (IMM after)</th>
<th>Group 3 (IMM before)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n = 50 %</td>
<td>n = 50 %</td>
<td>n = 50 %</td>
<td></td>
</tr>
<tr>
<td>≤100</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>101-300</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>301-500</td>
<td>10</td>
<td>20</td>
<td>35</td>
</tr>
<tr>
<td>501-700</td>
<td>30</td>
<td>60</td>
<td>9</td>
</tr>
<tr>
<td>701-900</td>
<td>7</td>
<td>14</td>
<td>4</td>
</tr>
<tr>
<td>&gt;900</td>
<td>3</td>
<td>6</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Systolic BP (mm Hg)</th>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>n = 50 %</td>
<td>n = 50 %</td>
<td>n = 50 %</td>
<td></td>
</tr>
<tr>
<td>00</td>
<td>00</td>
<td>11</td>
<td>10</td>
</tr>
<tr>
<td>1-5</td>
<td>2</td>
<td>4</td>
<td>36</td>
</tr>
<tr>
<td>6-10</td>
<td>31</td>
<td>62</td>
<td>1</td>
</tr>
<tr>
<td>11-15</td>
<td>10</td>
<td>20</td>
<td>1</td>
</tr>
<tr>
<td>16-20</td>
<td>6</td>
<td>12</td>
<td>1</td>
</tr>
<tr>
<td>&gt;20</td>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>
6 to 10 mm Hg, while 20% women showed decrease in systolic blood pressure in the range of 11 to 15 mm Hg, > 20 mm Hg fall was also observed in 2% women. In groups II and III maximum number of women showed decreased in systolic BP in the range of 1 to 5 mm Hg while in 20% of the women no change in blood pressure was found at all.

**DISCUSSION**

The observation of failure of uterus to contract in 6% of the cases of group I and resulting in immediate effective uterine contraction after intramyometrial injection in these cases is statistically borderline significant with a p-value of 0.047.

Blood loss during cesarean delivery occurs from incision through the abdominal wall, myometrium and the placental bed. Oxytocin is commonly administered after cesarean delivery to promote uterine contraction, thus reducing blood loss from the myometrium and the placental site. Hayashi RH et al\textsuperscript{11} demonstrated that effective pharmacological treatment of uterine atony is often achieved by an intramyometrial injection of PGF\textsubscript{2α} 250 µg.

Our data indicated that 5 IU oxytocin (group III) given intramyometrial before the separation of placenta results in considerable decrease in estimated blood loss at cesarean delivery than does 5 unit oxytocin intramyometrial after separation of placenta (group II) and 20 IU, continuous oxytocin infusion (group I), which is statistically highly significant (p = 0.0001).

Catanzarite VA\textsuperscript{12} did not find any difference in estimated blood loss during elective cesarean section between parturients who received 20 IU oxytocin intramyometrial and women who received 250 µg intramyometrial injections at this dose for routine cesarean section.

Sarna et al\textsuperscript{13} determined that uterine contractility and estimated blood loss was similar following 5 or 20 IU of oxytocin I/V, thus indicating that there is no benefit on uterine tone and blood loss of administering more than 5 IU oxytocin during elective cesarean section.

The observation of the systemic side effects of IV oxytocin infusion in group I was responsible for nausea and vomiting, whereas IMM oxytocin as given in groups II and III acts locally and the systemic side effects of IV oxytocin can be prevented by intramyometrial oxytocin thus, reducing the complication during cesarean delivery due to aspiration of vomitus which is statistically significant (p = 0.002).

The observation on hemodynamic changes in the form of decrease in blood pressure/tachycardia from baseline was less after intramyometrial injection than I/V administration.

The results of our study indicate that intramyometrial injection of 5 IU oxytocin after cesarean delivery is associated with a lesser decrease in blood pressure than 20 unit I/V oxytocin (continuous infusion) which is statistically highly significant (p = 0.0001).

It is well known that I/V bolus injection of oxytocin may result in short lived hypotension in nonpregnant women, during pregnancy and after cesarean delivery.\textsuperscript{14} The etiology of the observed hemodynamic changes is controversial and most likely multifactorial.

Kelvin C Dennehy et al\textsuperscript{15} determined blood pressure following intravenous and intramyometrial injection of oxytocin after cesarean delivery and observed that intramyometrial administration of 20 IU oxytocin after cesarean delivery is associated with more severe hypotension than is IV injection of 5 IU oxytocin. They stated that they did not expect intramyometrial oxytocin to be associated with more severe hypotension. According to them the most likely explanation for this finding is that intramyometrial oxytocin injector results in extensive rapid absorption of oxytocin from the myometrium into the systemic circulation.

The reason for difference in results of their study and our study may be due to the different dose of oxytocin used, i.e. 20 IU in their study and 5 IU in our study for intramyometrial injection.

In our experience, instituting prophylactic intramyometrial injection of oxytocin as soon as the baby is delivered has been associated with reduced average blood loss, lesser decrease in systolic blood pressure and less need for additional antiemetics.

**CONCLUSION**

To conclude, oxytocin remains the first-line drug in the prevention of uterine atonia in parturients undergoing cesarean section, especially due to its high therapeutic index. To reduce
the incidence of postpartum hemorrhage, its prophylactic use is justified. Regarding the route of administration, prophylactic intramyometrial oxytocin before delivery of placenta seems to increase uterine contractibility and reducing the blood loss during cesarean delivery and thus decreasing cesarean morbidity. There is less need for antiemetics and there are less hemodynamic changes, i.e. hypotension and tachycardia which can be detrimental in women with low cardiac reserve or hypovolemia.

REFERENCES


ABOUT THE AUTHORS

Divya Mangla (Corresponding Author)
Assistant Professor, Department of Obstetrics and Gynecology, Subharti Medical College, Bye-Pass Road, Meerut-250002, Uttar Pradesh, India
Phone: 09758852575, e-mail: drdivyagoel@rediffmail.com

JK Goel
Associate Professor, Department of Obstetrics and Gynecology, Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly, Uttar Pradesh, India

Ruchica Goel
Senior Resident, Department of Obstetrics and Gynecology, Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly, Uttar Pradesh, India